Cognito Therapeutics just announced a $73 million funding round to support clinical trials of their GammaSense neuromodulation treatment. Early studies showed significant slowing of cognitive decline (though not reversal).
Big News, Money in Neurostimulation for Cognitive Decline; Pharma Not Worried